INMB logo

INMUNE BIO INC

INMBNASDAQ
πŸ† #4457 by market capEarnings Mar 29 Β· PostUS Equity
β€”β€”
Quote unavailable
πŸ””
Track INMB
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$26M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
512.1x
Expensive
Otter Score
β€”
Insufficient data
No chart data available for INMB.

Trading Snapshot

Day Range
β€”
52-Week Range
$0.82 – $2.60
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
31.0M
Next Earnings
2027-03-29

Fundamentals Snapshot

Annual Revenue
$50,000
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
512.1x
EPS (TTM)
$-0.69
Dividend Yield
β€”
Dilution (1yr)
+19.3%
INMB logo

INMUNE BIO INC

INMB
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$50Kβ–² +257.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%β–² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$31Mβ–Ό βˆ’27.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$24Mβ–Ό βˆ’29.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
26.6Mβ–² +19.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$24Mβ–² +$3M YoY
StockOtter Β· stockotter.space

About INMUNE BIO INC

INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.